



Australian Government
Department of Health and Ageing
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

I, PETER KAYLOCK, Acting Head, Office of Devices Authorisation, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health and Ageing for the purposes of section 42 DK (1) of the Therapeutic Goods Act, give notice that the restricted representations described in paragraph (a) below, being representations that are necessary for the appropriate use of the therapeutic goods described in paragraph (b) below, may be included either on the label of the package of those goods or in information included in the package in which those goods are contained:

- (a) representations to the effect that the goods described in paragraph (b) below may be used **“For the treatment of patients with known cardiovascular or cerebrovascular disease, as an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischaemic attack and cerebrovascular accident (stroke).”**
- (b) **MEDI CHOICE LOW DOSE ASPIRIN 100mg enteric coated tablet blister pack**
supplied as an over-the-counter drug by Nova Pharmaceuticals Australasia Pty Ltd.

Dated this 14th day of September 2010.

A handwritten signature in black ink, appearing to read 'Peter Kaylock', with a long horizontal flourish extending to the right.

PETER KAYLOCK
Delegate of the Secretary to the Department of
Health and Ageing